

Supplementary material

A label-free screening approach targeted protease- activated receptor 1 based on dynamic mass redistribution in living cells

Weiwei Tang^a, Bixia Huang^a, Jiancheng Wang^a, Lin An^a, Huailing Zhong^b, Hua
Yang^a, Ping Li^a, Jun Chen^{a,*}

^a*State Key Laboratory of Natural Medicines, China Pharmaceutical University,*

Nanjing 210009, P. R. China

^b*U-Pharm Laboratories LLC, 239 New Rd, Suite A-107, Parsippany, NJ 07054 USA*

Abbreviations: PAR-1, protease activated receptor 1; DMR, dynamic mass redistribution.

* Corresponding author. Tel.: +86-25-8327-1382; Fax: +86-25-8327-1379 (J. Chen);
E-mail address: chenj2002cpu@126.com (J. Chen).




Fig S1 Concentration effect curves resulting from different indicators after thrombin

activating in different cell types, indicators: maximum amplitude of 10min poststimulation (MAX_{10min}), DMR responses from 30min time points poststimulation (30min), area under the response curve (AUC_{50min}); cell types: A), B) and C) CHO-K1; D), E) and F) hAECs; G), H) and I) HUVEC; J), K) and L) EA.hy.926; M), N) and O) MDA-MB-231; P), Q) and R) A431.






Fig S2 Concentration effect curves resulting from different indicators after TRAP-6 activated in different cell types, indicators: maximum amplitude of 10min

poststimulation (MAX_{10min}), DMR responses from 30min time points poststimulation (30min), area under the response curve (AUC_{50min}); cell types: A), B) and C) CHO-K1; D), E) and F) hAECs; G), H) and I) HUVEC; J), K) and L) EA.hy.926; M), N) and O) MDA-MB-231; P), Q) and R) A431.



FigS3 MTT assay for preliminary screened out compounds (potent compounds, data represent as mean \pm S.D.) ($n=5$)



FigS4 Chemical structures of eight screened out compounds from DMR secondary screening assay